|The full article is available to subscribers||Subscriber Login|
The FDA has approved a sumatriptan iontophoretic transdermal system (Zecuity – Teva) for acute treatment of migraine in adults. Sumatriptan, the first of seven serotonin 1B/1D-receptor agonists (triptans) approved for this indication, is the most frequently prescribed migraine treatment in the US. It is also available in oral, intranasal, and injectable formulations.
RATIONALE FOR A PATCH — Patients with migraine who also have nausea, vomiting, or gastroparesis may not be able to take or absorb an oral triptan. Nasal sprays have a more rapid onset of action than oral formulations (10-15 vs 30-60 minutes), but they can have an unpleasant taste and they also depend on gastrointestinal absorption of the significant portion of the dose that is swallowed. Subcutaneously administered sumatriptan is the fastest acting (about 10 minutes) and most effective triptan formulation, but it causes more... more
- Drugs for migraine. Treat Guidel Med Lett 2013; 11:107.
- M Vikelis et al. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. Neuropsychiatr Dis Treat 2012; 8:429.
- MW Pierce. Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics 2010; 7:159.
- J Goldstein et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012; 52:1402.
- TR Smith et al. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache 2012; 52:612.